雄激素受体(AR)在HER-2过表达型乳腺癌中的作用及机制研究进展  

Research progress of the role and mechanism of AR in HER-2 overexpressing breast cancer

作　　者：吴洋 宋燕妮[1] WU Yang;SONG Yanni(Department of Breast Surgery,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.)

机构地区：[1]哈尔滨医科大学附属肿瘤医院乳腺外科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2021年第16期2913-2917,共5页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:81302286/H1622);中国博士后科学基金项目(编号:2016M590209);教育部“春晖计划”合作科研项目(编号:HLJ2019010);黑龙江省自然科学基金项目(编号:LH2020H120);哈医大附属肿瘤医院海燕科研基金项目(编号:JJZD2020-04)。

摘　　要：人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)过表达型乳腺癌是乳腺癌中具有侵袭性的亚型之一,与其他类型乳腺癌相比,此类型疾病进展迅速,易复发转移,且预后差。近年来,研究表明雄激素受体(androgen receptor,AR)在HER-2过表达型乳腺癌中高表达。因此,本文将对AR在HER-2过表达型乳腺癌中的作用机制,对预后的影响及最新研究进展进行综述,以期为未来研究提供新的思路。Human epidermal growth factor receptor-2(HER-2)overexpressing breast cancer is one of the aggressive subtypes of breast cancer,compared with other types of breast cancer,this type of disease progresses rapidly,is prone to recurrence and metastasis,and has a poor prognosis.In recent years,studies have confirmed that androgen receptor(AR)is highly expressed in HER-2 overexpressing breast cancer.Therefore,this article will review the mechanism of AR in HER-2 overexpressing breast cancer,its impact on prognosis,and the latest research progress,in order to provide new ideas for future research.

关 键 词：雄激素受体 HER-2过表达型乳腺癌 表达及预后 

分 类 号：R737.9[医药卫生—肿瘤]